Skip to main content

Table 2 Clinical trials investigating neutrophil-targeting agents in TNBC

From: Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance

Target

Intervention

Effects on neutrophils

Status

Clinical trial ID

COX-2

Celebrex

Downregulation of Arg1, Nos2 and COX-2

Completed

NCT00056082

HDACs

Suberoylanilide hydroxamic acid

Inhibiting immunosuppression

Withdrawn

NCT01695057

HDACs

Belinostat

Inhibiting immunosuppression

Recruiting

NCT04315233

HDACs

Vorinostat

Inhibiting immunosuppression

Completed

NCT00574587

HDACs

Entinostat

Inhibiting immunosuppression

Completed

NCT02708680

PTKs

Sorafenib, Apatinib, Famitinib

Induction of apoptosis

Recruiting

NCT05594095

TGFβ

Fresolimumab

Neutralizing TGFβ

Completed

NCT01401062

TGFBR1

Galunisertib

Inhibiting TGFβ receptor I

Active, not recruiting

NCT02672475